CA-125 reduction during neoadjuvant chemotherapy is associated with success of cytoreductive surgery and outcome of patients with advanced high-grade ovarian cancer.
Roy KessousMichel D WissingSabrina PiedimonteJeremie AbitbolLiron KoganIdo LaskovAmber YasmeenShannon SalvadorSusie LauWalter H GotliebPublished in: Acta obstetricia et gynecologica Scandinavica (2020)
Reduction of CA-125 levels during neoadjuvant chemotherapy provides an early predictive tool that strongly correlates with successful cytoreductive surgery and long-term clinical outcome in women with advanced high-grade serous and endometrioid ovarian cancer.
Keyphrases
- neoadjuvant chemotherapy
- high grade
- low grade
- minimally invasive
- locally advanced
- coronary artery bypass
- lymph node
- sentinel lymph node
- surgical site infection
- rectal cancer
- squamous cell carcinoma
- metastatic renal cell carcinoma
- protein kinase
- radiation therapy
- endometrial cancer
- percutaneous coronary intervention
- coronary artery disease
- acute coronary syndrome